Thyroid Dysfunction in Diabetes: From Association to Action

Dear Editor, Re: Evaluating the Prevalence and Predictors of Thyroid Dysfunction in Patients with Type 2 Diabetes Mellitus.[1] Shrewastwa et al.[1] present important data on the burden of thyroid dysfunction among patients with type 2 diabetes mellitus (T2DM), reporting a prevalence approaching 1 in 5. This finding is consistent with broader epidemiological evidence demonstrating that thyroid abnormalities frequently coexist with metabolic disorders, particularly in populations with high rates of obesity, and insulin resistance.[2] In addition to providing useful prevalence estimates, there are several interpretive considerations related to the study’s findings. One such consideration is that the study is cross-sectional in nature. This limits the ability to draw any conclusions about the existence of causal relationships between T2DM and thyroid dysfunction. While there is an association between the two, longitudinal studies have indicated the potential for chronic low-level inflammation, excessive body fat (adiposity), and insulin resistance to affect the thyroid axis over a period of time.[2] The plausibility of causation could be enhanced through prospective studies that include metabolic adaptations over time. In addition, there is an ongoing deficiency regarding the lack of a defined standard laboratory test for thyroid screening within the field of diabetes care. Where current evidence-based guidelines recommend selective screening for patients with diabetes, recent meta-analytic research indicates that subclinical hypothyroidism, even in patients with T2DM, can significantly increase the risk for cardiovascular and glucose-related complications.[3] The results of this study also indicate that the screening threshold may need to be changed for specific high-risk subsets of the diabetic populations (i.e., older adults as well as those who have multiple cardiometabolic risk factors). In addition, new evidence from low-resource countries supports the idea that implementing structured thyroid screening among people with T2DM is both attainable and cost-effective, especially among populations with elevated baseline cardiovascular/renal complication rates.[4] Such insights are highly relevant to India and other low- and middle-income countries facing similar epidemiological transitions. Finally, guideline-based management of hypothyroidism underscores the importance of early identification and appropriate treatment to mitigate long-term metabolic and cardiovascular risks.[5] The integration of thyroid risk stratification into diabetes care paths will likely create the greatest impact on integrating diabetes and chronic disease management into routine practice. The authors of this article, Shrewastwa and colleagues, encourage the implementation of improved screening strategies, the continuation of longitudinal studies on thyroid function and diabetes, and recommendations regarding the incorporation of endocrine assessments into diabetes care systems to improve patient health care outcomes and contribute to evidence-based policy development through improving inclusion of thyroid function assessments into diabetes care systems. Author contribution M. Vijayasimha: Conceptualization, literature review, interpretation of evidence, manuscript drafting, critical revision of the manuscript, and approval of the final version for publication. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.